References
- Martínez-GarcíaMAPerpiñá-TorderaMSoler-CataluñaJJRomán-SánchezPLloris-BayoAGonzález-MolinaADissociation of lung function, dyspnea ratings and pulmonary extension in bronchiectasisResp Med200710122482253
- ChalmersJDGoemnnePAlibertiSThe Bronchiectasis Severity Index. An International derivation and validation studyAm J Respir Crit Care Med201418957658524328736
- Martinez-GarciaMAde GraciaJVendrellMMultidimensional approach to non-cystic fibrosis bronchiectasis: the FACED scoreEur Respir J2014431357136724232697
- EllisHCCowmanSFernandesMWilsonRLoebingerMRPredicting mortality in bronchiectasis using bronchiectasis severity index and FACED scores: a 19-year cohort studyEur Resp J201647482489
- Martinez-GarciaMAAthanazioRGramblickaGInternational validation of FACED score in 672 patients with non-cystic fibrosis bronchiectasisATS Congress2016San Francisco Abstract 10559
- McDonnellMJAlibertiSGoeminnePCMultidimensional severity assessment in bronchiectasis: an analysis of seven European cohortsThorax Epub2016811
- Martinez-GarciaMASoler-CataluñaJJPerpiñáMRománPSorianoJFactors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasisChest20071321565157217998359
- Martinez-GarciaMAVendrellMGirónRThe multiple faces of non-cystic fibrosis bronchiectasis: a cluster analysis approachAnn Am Thorac Soc2016131468147527348199
- AlibertiSLonniSDoreSClinical phenotypes in adult patients with bronchiectasisEur Respir J2016471113112226846833
- De la RosaDMartinez-GarciaMAOlveiraCGirónRMaizLPradosCAnnual direct medical costs of bronchiectasis treatment: impact of severity, exacerbations, chronic bronchial infection and COPD coexistenceChron Respir Dis Epub2016412
- AltenburgJde GraaffCSStienstraYEffect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trialJAMA2013309121251125923532241
- BarkerAFO’DonnellAEFlumePAztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trialsLancet Respir Med20142973874925154045
- HaworthCSFowerakerJEWilkinsonPInhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infectionAm J Respir Crit Care Med2014189897598224625200
- SerisierDJMartinMLMcGuckinMAEffect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trialJAMA2013309121260126723532242
- WilsonRWelteTPolverinoECiprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised studyEur Respir J20134151107111523018904
- WongCJayaramLKaralusNAzithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trialLancet2012380984266066722901887
- NaidichDPMcCauleyDIKhouriNFStitikFPSiegelmenSSComputed tomography of bronchiectasisJ Comput Assist Tomogr198264374447096687
- HanleyJAMcNeilBJThe meaning and use of the area under a receiver operating characteristic (ROC) curveRadiology198214329367063747
- SeitzAEOlivierKNAdjenianJHollandSMPrevotsRTrends in bronchiectasis among Medicare beneficiaries in the United States, 2000 to 2007Chest201214243243922302301
- RobertsHJHubbardRTrends in bronchiectasis mortality in England and WalesResp Med2010104981985
- RingshausenFCde RouxAPletzMWHämäläinenNWelteTRademacherJBronchiectasis-associated hospitalizations in Germany, 2005–2011: a population-based study of disease burden and trendsPLoS One20138e7110923936489
- SeitzAEOlivierKNSteinerCAMontes de OcaRHollandSMPrevotsDRTrends and burden of bronchiectasis-associated hospitalizations in the United States, 1993–2006Chest201013894494920435655